Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers
- First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer
- New data from the phase III IMpower010 study provide further insights into the role of Tecentriq® (atezolizumab) in early-stage non-small cell lung cancer (NSCLC)
- Genomic data from the phase II CUPISCO study in Cancer of Unknown Primary (CUP), an uncommon type of cancer with high unmet need, could support diagnostics and more personalised treatment plans
Basel, 07 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new oncology data will be presented at the European Society for Medical Oncology (ESMO) Congress, which will be held 16-21 September, 2021. With one of the broadest oncology pipelines and portfolios in the industry, Roche presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung cancer, and a presentation on cancer of unknown primary (CUP), which has been selected for inclusion in the ESMO Press Programme.
“Our data at ESMO 2021 show how we continue to pursue potentially transformative advances in breast and lung cancer, particularly in earlier stage settings where the chance for cure is highest,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Furthermore our efforts in personalised healthcare, exemplified by our insights in CUP, will help address the needs of many patients who are diagnosed at a late stage.”
Breast Cancer Highlights
First phase II data will be presented from an interim analysis of giredestrant, a next-generation oral selective oestrogen receptor degrader (SERD), in neoadjuvant, ER-positive, HER2-negative early breast cancer. Over 70% of breast cancer cases are hormone receptor (HR)-positive, and there is a need for more effective and tolerable treatments, since up to 30% of patients develop resistance to standard of care treatments and in the adjuvant setting half of patients stop treatment due to the toll of side effects. Our efforts in this area represent a step towards making the treatment of patients with HR-positive breast cancer more effective and less debilitating in order to reduce the burden of treatment. This study further showcases Roche’s commitment to identifying meaningful treatment options for patients with breast cancer through a comprehensive development programme that includes early and late-stage HR-positive, HER2 positive and triple-negative forms of the disease.
Lung Cancer Highlights
New results from the phase III IMpower010 study, to be presented during Presidential Symposium Three, highlight patterns of relapse and subsequent therapy following treatment with Tecentriq® (atezolizumab) versus standard of care in early lung cancer, and help to define how Tecentriq fits into the adjuvant treatment pathway. These findings are particularly important as real-world data, which will also be presented at ESMO, will provide detail on the proportion of people with early NSCLC in the United States who do not receive adjuvant treatment despite guidelines recommending that they do so. These real world data also highlight survival outcomes in this setting and reinforce the need for more effective adjuvant therapy in NSCLC, as half of all people with early-stage lung cancer today still experience disease recurrence following surgery.
The phase III IMpower010 study showed adjuvant Tecentriq improved disease-free survival in PD-L1-positive early-stage lung cancer, compared with best supportive care - a first in cancer immunotherapy. Based on the outcomes from this study, the United States Food and Drug Administration recently granted Priority Review under the Real-Time Oncology Review pilot programme to Tecentriq as an adjuvant treatment for certain people with early NSCLC, and is expected to make a decision later this year.
Innovation in Personalised Healthcare
Latest results from a preliminary descriptive molecular analysis based on the CUPISCO study, which will be featured in the ESMO Press Programme, shed further light on the genomic profiles of patients with poor-prognosis CUP. These results highlight the importance of comprehensive genomic profiling for patients with CUP and identify therapeutically relevant genomic alterations in a significant proportion of patients, which may help to inform a more personalised treatment plan. In CUP, doctors cannot identify the location of the original (primary) tumour and can only find metastases. This causes practical problems since traditional treatment approaches rely on the site of origin being known, and as such, most patients are treated with nonspecific chemotherapy. Unfortunately, prognosis remains poor and the median survival following diagnosis is just six to 12 months, reinforcing the need for improved diagnosis and treatment.
Real world data from the United States examining the use of Foundation Medicine’s comprehensive genomic testing prior to first-line therapy in patients with metastatic colorectal cancer (mCRC) will also be presented and underpin Roche’s efforts to drive more widespread and earlier testing for patients with cancer.
Ahead of ESMO, Roche will also be hosting a virtual Personalised Healthcare in Oncology Symposium for healthcare professionals on Thursday 9 September, 13:00 – 14:30 CEST. In this symposium, different healthcare system experts from across the world will discuss how new and emerging solutions in personalised healthcare can help to improve patient outcomes, and ultimately their quality of life.
LinkedIn Live event - COVID-19 and Cancer: Reshaping Patient Care in the Context of the Pandemic Today and Tomorrow
Roche will also be hosting a live roundtable discussion on Wednesday 15 September 2021, 16:00 CEST that will focus on the global efforts to overcome the impact of the COVID-19 pandemic on cancer outcomes. The discussion, featuring experts from medical societies, academia and patient groups, will focus on what lessons have been learned so far, and how stakeholders can forge new paths and partnerships to find and deliver solutions for patients and society. Join this event on Roche’s LinkedIn page here.
Roche Oncology Newsroom
Roche’s ESMO Oncology Newsroom will be available from Tuesday 7 September for journalists to access exclusive materials sharing insights into Roche’s latest data, vision and strategy to pursue and advance scientific progress in order to improve the lives of people living with cancer. To access the newsroom, please register here.
Overview of key presentations featuring Roche medicines
|Medicine||Abstract title||Abstract or presentation number|
|Giredestrant||Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase 2 coopERA BC study||LBA14|
|Kadcyla||Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): data from the phase 3 EMILIA study||284P|
|Kadcyla||Trial in progress - ASTEFANIA: A phase 3 study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy||202TiP|
|Kadcyla||Trial in progress - KATE3: A phase 3 study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer||329TiP|
|Real world data||Real-world Outcomes of Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) metastatic Breast Cancer (mBC) with High Tumor Mutational Burden (hTMB) Treated with Immune Checkpoint Inhibitors (ICI)||237P|
|Tecentriq||IMpower010: Patterns of relapse and subsequent therapy from a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in stage IB-IIIA non-small cell lung cancer (NSCLC)||LBA9|
|Tiragolumab||Trial in progress - SKYSCRAPER-03: Phase III, Open-Label Randomised Study of Atezolizumab + Tiragolumab vs Durvalumab in Patients with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed After Platinum-based Concurrent Chemoradiation (cCRT)||1190TiP|
|Atezolizumab||Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first line (1L) advanced/metastatic (m)NSCLC: results of the Blood First Assay Screening Trial (BFAST) Phase 3 Cohort C||1281O|
|Real world data||Real-world Adjuvant Treatment Patterns and Survival Outcomes among early NSCLC US Patients||1158P|
|Real world data||Adoption and early clinical outcomes of atezolizumab (atezo) + carboplatin and etoposide (CE) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the real-world (RW) setting||1650P|
|Atezolizumab||Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)||658MO|
|Atezolizumab||Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-Gastric Cancer||1382P|
|Head and neck cancer|
|Tiragolumab||Trial in progress - SKYSCRAPER-09: A Phase II, Randomised, Double-blinded Study of Atezolizumab (Atezo) + Tiragolumab (Tira) and Atezo + Placebo as First-line (1L) Therapy for Recurrent/Metastatic (R/M) PD-L1+ Squamous Cell Carcinoma of the Head and Neck (SCCHN)||927TiP|
|Atezolizumab||IMbrave150: exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) + bevacizumab (bev) or sorafenib (sor)||932P|
|Tumour agnostic treatment and personalised healthcare|
|Comprehensive genomic profiling||Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO||1804P|
|Comprehensive genomic profiling||Fusion and rearrangement (RE) detection using DNA and RNA-based comprehensive genomic profiling (CGP) of sarcomas||1532P|
|Comprehensive genomic profiling||Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations||457P|
|Tumour agnostic||Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN||80P|
|Real world data||Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and Treatment Patterns in the real-world (RW) setting||1301P|
|Real world data||Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)||477P|
About Roche in Oncology
Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast. The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa®(alectinib); Avastin®(bevacizumab); Cotellic®(cobimetinib); Erivedge®(vismodegib); Gavreto®(pralsetinib); Gazyva®/Gazyvaro®(obinutuzumab); Herceptin®(trastuzumab); Kadcyla®(trastuzumab emtansine); MabThera®/Rituxan®(rituximab); Perjeta®(pertuzumab); Polivy®(polatuzumab vedotin); Tarceva®(erlotinib); Rozlytrek®(entrectinib); Tecentriq®(atezolizumab); Venclexta®/Venclyxto®(venetoclax) in collaboration with AbbVie; Xeloda®(capecitabine); Zelboraf®(vemurafenib). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more information on Roche’s approach to cancer, visit www.roche.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
| Dr. Nicolas Dunant|
Phone: +41 61 687 05 17
| Patrick Barth|
Phone: +41 61 688 44 86
| Dr. Barbara von Schnurbein|
Phone: +41 61 687 89 67
| Karsten Kleine|
Phone: +41 61 682 28 31
| Nina Mählitz|
Phone: +41 79 327 54 74
| Nathalie Meetz|
Phone: +41 61 687 43 05
|Roche Investor Relations|
| Dr. Karl Mahler|
Phone: +41 61 68-78503
| Jon Kaspar Bayard|
Phone: +41 61 68-83894
| Dr. Sabine Borngräber|
Phone: +41 61 68-88027
| Dr. Bruno Eschli|
Phone: +41 61 68-75284
| Dr. Birgit Masjost|
Phone: +41 61 68-84814
| Dr. Gerard Tobin|
Phone: +41 61 68-72942
|Investor Relations North America|
| Loren Kalm|
Phone: +1 650 225 3217